- OncoTree
- ENCG
Loading cancer entity…
Loading cancer entity…
Clinical trials
328 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (51)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06047379 | Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis | recruiting | Phase 1 / Phase 2 | 134 | Neonc Technologies, Inc.INDUSTRY | 1 | Sep 24, 2026 | clinicaltrials |
| NCT05555550 | Evaluation of 18F-Fluciclovine Positron Emission Tomography - Magnetic Resonance Imaging (PET-MRI) in LGG | recruiting | Early Phase 1 | 30 | Children's Hospital of PhiladelphiaOTHER | 1 | Sep 22, 2026 | clinicaltrials |
| NCT06804655 | Pharmacoscopy for Patients With Refractory Primary Brain Tumors(EViDENCE-BT) | recruiting | Phase 2 | 40 | University of ZurichOTHER | 1 | Sep 21, 2026 | clinicaltrials |
| NCT04166409 | A Study of the Drugs Selumetinib vs. Carboplatin and Vincristine in Patients With Low-Grade Glioma | recruiting | Phase 3 | 170 | National Cancer Institute (NCI)NIH | 3 | Sep 11, 2026 | clinicaltrials |
| NCT04923126 | SJ901: Evaluation of Mirdametinib in Children, Adolescents, and Young Adults With Low-Grade Glioma | recruiting | Phase 1 / Phase 2 | 132 | St. Jude Children's Research HospitalOTHER | 1 | Sep 11, 2026 | clinicaltrials |
| NCT07061626 | Determine Maximum Tolerated Dose, Safety, and Tolerability of Rhenium (186Re) in Pediatric Recurrent, Refractory or Progressive Ependymoma and High-Grade Glioma | recruiting | Phase 1 | 56 | CerenomeINDUSTRY | 1 | Sep 11, 2026 | clinicaltrials |
| NCT06410248 | Triapine in Combination With Temozolomide for the Treatment of Patients With Recurrent Glioblastoma | recruiting | Phase 1 | 22 | Northwestern UniversityOTHER | 1 | Sep 9, 2026 | clinicaltrials |
| NCT06989086 | FearLess in NeuroOncology | recruiting | N/A | 112 | Virginia Commonwealth UniversityOTHER | 1 | Sep 9, 2026 | clinicaltrials |
| NCT07110246 | Dabrafenib and Trametinib for BRAF V600 Mutant Low-Grade Gliomas(PNOC037) | recruiting | Phase 2 | 96 | University of California, San FranciscoOTHER | 1 | Sep 3, 2026 | clinicaltrials |
| NCT07390539 | B7-H3.CD28Z.CART in CNS Neoplasms | recruiting | Phase 1 | 70 | Robbie MajznerOTHER | 1 | Sep 3, 2026 | clinicaltrials |
| NCT04374305 | Innovative Trial for Understanding the Impact of Targeted Therapies in NF2-Related Schwannomatosis (INTUITT-NF2)(INTUITT-NF2) | recruiting | Phase 2 | 109 | Scott R. Plotkin, MD, PhDOTHER | 1 | Sep 2, 2026 | clinicaltrials |
| NCT06860594 | Testing the Addition of an Anti-Cancer Drug, Triapine, to the Usual Radiation Therapy for Recurrent Glioblastoma or Astrocytoma | recruiting | Phase 1 | 30 | National Cancer Institute (NCI)NIH | 1 | Sep 2, 2026 | clinicaltrials |
| NCT06161974 | Study of Olutasidenib and Temozolomide in HGG | recruiting | Phase 2 | 60 | Rigel PharmaceuticalsINDUSTRY | 7 | Sep 1, 2026 | clinicaltrials |
| NCT05303519 | SIGMA (Safusidenib in IDH1 Mutant Glioma Maintenance)(SIGMA) | recruiting | Phase 3 | 365 | Nuvation Bio Inc.INDUSTRY | 3 | Aug 28, 2026 | clinicaltrials |
| NCT05857969 | Ex Vivo Drug Sensitivity Testing and Multi-Omics Profiling | recruiting | Phase 1 | 65 | Florida International UniversityOTHER | 1 | Aug 26, 2026 | clinicaltrials |
| NCT05180825 | Pediatric Low Grade Glioma - MEKinhibitor TRIal vs Chemotherapy(PLGG - MEKTRIC) | recruiting | Phase 2 | 134 | University Hospital, Strasbourg, FranceOTHER | 1 | Aug 20, 2026 | clinicaltrials |
| NCT04485559 | Trametinib and Everolimus for Treatment of Pediatric and Young Adult Patients With Recurrent Gliomas (PNOC021) | recruiting | Phase 1 | 50 | University of California, San FranciscoOTHER | 1 | Aug 18, 2026 | clinicaltrials |
| NCT06161519 | PLX038 in Primary Central Nervous System Tumors Containing MYC or MYCN Amplifications | recruiting | Phase 1 / Phase 2 | 146 | National Cancer Institute (NCI)NIH | 1 | Aug 12, 2026 | clinicaltrials |
| NCT05057702 | Individualized Treatment Plan in Children and Young Adults With Relapsed Medulloblastoma and Ependymoma(PNOC027) | recruiting | N/A | 74 | University of California, San FranciscoOTHER | 1 | Aug 11, 2026 | clinicaltrials |
| NCT06666348 | Phase 1/2 Study of Mirdametinib + Vinblastine for Newly Diagnosed/Previously Untreated PLGG + Activation of MAPK(MIRV) | recruiting | Phase 1 / Phase 2 | 50 | St. Justine's HospitalOTHER | 1 | Aug 11, 2026 | clinicaltrials |
| NCT05503797 | A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations | recruiting | Phase 2 | 254 | Fore BiotherapeuticsINDUSTRY | 12 | Jul 27, 2026 | clinicaltrials |
| NCT04479696 | Customized Neuro-Imaging Referenced Symptom Video for the Reduction of Patient and Caregiver Anxiety Around Radiation Treatment for Brain Tumors | recruiting | N/A | 117 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 20, 2026 | clinicaltrials |
| NCT04623931 | Chemotherapy and Radiation Therapy for the Treatment of IDH Wildtype Gliomas or Non-histological (Molecular) Glioblastomas | recruiting | Phase 2 | 40 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 16, 2026 | clinicaltrials |
| NCT03948490 | Rehabilitation and Longitudinal Follow-up of Cognition in Adult Lower Grade Gliomas | recruiting | N/A | 117 | University of California, San FranciscoOTHER | 1 | Jul 14, 2026 | clinicaltrials |
| NCT06712875 | MAPK Inhibition Combined With Anti-PD1 Therapy for BRAF-altered Pediatric Gliomas | recruiting | Phase 1 / Phase 2 | 27 | Ann & Robert H Lurie Children's Hospital of ChicagoOTHER | 1 | Jul 10, 2026 | clinicaltrials |
| NCT07468136 | Retifanlimab With or Without Difluoromethylornithine for the Treatment of Progressive High Grade Gliomas | recruiting | Phase 1 / Phase 2 | 33 | Mayo ClinicOTHER | 1 | Jun 24, 2026 | clinicaltrials |
| NCT06193759 | Immunotherapy for Malignant Pediatric Brain Tumors Employing Adoptive Cellular Therapy (IMPACT)(IMPACT) | recruiting | Phase 1 | 12 | Children's National Research InstituteOTHER | 1 | Jun 17, 2026 | clinicaltrials |
| NCT04732065 | ONC206 for Treatment of Newly Diagnosed, Recurrent Diffuse Midline Gliomas, and Other Recurrent Malignant CNS Tumors(PNOC023) | recruiting | Phase 1 | 208 | Sabine Mueller, MD, PhDOTHER | 3 | Jun 11, 2026 | clinicaltrials |
| NCT07631338 | Low-grade Gliomas in Argentina: Incidence, Survival, and Therapeutic Strategies | recruiting | — | 40 | Hospital Italiano de Buenos AiresOTHER | 1 | Jun 8, 2026 | clinicaltrials |
| NCT06607692 | Study in Children and Adolescents of 177Lu-DOTATATE (Lutathera®) Combined With the PARP Inhibitor Olaparib for the Treatment of Recurrent or Relapsed Solid Tumours Expressing Somatostatin Receptor (SSTR) (LuPARPed).(LUPARPED) | recruiting | Phase 1 / Phase 2 | 25 | Fundación de investigación HMOTHER | 1 | Jun 4, 2026 | clinicaltrials |
| NCT07223034 | A Study of 177Lu-PSMA-617 in People With Gliomas | recruiting | Phase 1 | 20 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jun 4, 2026 | clinicaltrials |
| NCT06254326 | ADAGiO: Adoptive Cellular Therapy for the TreAtment of Recurrent OliGodendrogliOma (OG) Adult Patients(ADAGiO) | recruiting | Phase 1 | 12 | University of FloridaOTHER | 1 | May 27, 2026 | clinicaltrials |
| NCT07424092 | Intratumoral DNX-2401 for High Grade Pediatric Brain Tumors(PED-DNX2401) | recruiting | Phase 2 | 39 | Clinica Universidad de Navarra, Universidad de NavarraOTHER | 2 | May 27, 2026 | clinicaltrials |
| NCT03750513 | LET Optimized IMPT in Treating Pediatric Patients With Ependymoma | recruiting | Phase 1 | 48 | M.D. Anderson Cancer CenterOTHER | 1 | May 20, 2026 | clinicaltrials |
| NCT06964737 | Anti-GARP Chimeric Antigen Receptor T Cell Therapy for the Treatment of Recurrent Grade III or IV Gliomas | recruiting | Phase 1 | 30 | Ohio State University Comprehensive Cancer CenterOTHER | 1 | May 8, 2026 | clinicaltrials |
| NCT05190172 | PRO-GLIO: PROton Versus Photon Therapy in IDH-mutated Diffuse Grade II and III GLIOmas(PRO-GLIO) | recruiting | N/A | 225 | Oslo University HospitalOTHER | 1 | May 1, 2026 | clinicaltrials |
| NCT04540107 | Serial MR Imaging and MR Spectroscopic Imaging for the Characterization of Lower Grade Glioma | recruiting | Phase 1 | 300 | Susan ChangOTHER | 1 | Apr 29, 2026 | clinicaltrials |
| NCT04185038 | Study of B7-H3-Specific CAR T Cell Locoregional Immunotherapy for Diffuse Intrinsic Pontine Glioma/Diffuse Midline Glioma and Recurrent or Refractory Pediatric Central Nervous System Tumors | recruiting | Phase 1 | 90 | Seattle Children's HospitalOTHER | 1 | Apr 13, 2026 | clinicaltrials |
| NCT07506239 | Efficacy of Laser Interstitial Thermal Therapy in Young Persons With Low-grade Glioma | recruiting | N/A | 40 | University of California, San FranciscoOTHER | 1 | Apr 1, 2026 | clinicaltrials |
| NCT05345002 | All-Trans Retinoic Acid (ATRA) Plus PD-1 Inhibition in Recurrent IDH-Mutant Glioma | recruiting | Phase 2 | 55 | Stephen Bagley, MD, MSCEOTHER | 1 | Feb 20, 2026 | clinicaltrials |
| NCT06132685 | Post-Operative Dosing of Dexamethasone in Patients With Brain Tumors After a Craniotomy, PODS Trial | recruiting | Phase 2 | 200 | Emory UniversityOTHER | 1 | Feb 10, 2026 | clinicaltrials |
| NCT05331521 | A Clinical Study to Improve Brain Function and Quality of Life of Patients With Newly Diagnosed Brain Tumors (Gliomas).(ImproveCodel) | recruiting | Phase 3 | 406 | University Hospital HeidelbergOTHER | 1 | Feb 3, 2026 | clinicaltrials |
| NCT04702581 | A Randomized Trial of Delayed Radiotherapy in Patients Low-grade Oligodendrogliomas Requiring a Treatment Other Than Surgery(POLO) | recruiting | Phase 3 | 280 | Hospices Civils de LyonOTHER | 1 | Jan 29, 2026 | clinicaltrials |
| NCT04865315 | A Living Tissue Bank of Patient-Derived Organoids From Glioma Tumors(HiLoGlio) | recruiting | — | 50 | Maastricht Radiation OncologyOTHER | 1 | Jan 27, 2026 | clinicaltrials |
| NCT05106296 | Chemo-immunotherapy Using Ibrutinib Plus Indoximod for Patients With Pediatric Brain Cancer | recruiting | Phase 1 | 37 | Theodore S. JohnsonOTHER | 1 | Jan 9, 2026 | clinicaltrials |
| NCT02358187 | A Vaccine Trial for Low Grade Gliomas | recruiting | Phase 2 | 25 | James FelkerOTHER | 1 | Jan 7, 2026 | clinicaltrials |
| NCT04541082 | Phase I Study of Oral ONC206 in Recurrent and Rare Primary Central Nervous System Neoplasms | recruiting | Phase 1 | 102 | Jazz PharmaceuticalsINDUSTRY | 1 | Dec 18, 2025 | clinicaltrials |
| NCT05259605 | Observational Study for Assessing Treatment and Outcome of Patients With Primary Brain Tumours Using cIMPACT-NOW and 2021 WHO Classification | recruiting | — | 1,650 | European Organisation for Research and Treatment of Cancer - EORTCNETWORK | 12 | Dec 17, 2025 | clinicaltrials |
| NCT05956821 | Treatment of Relapsed/Refractory Intracranial Glioma in Patients Under 22 Years of Age | recruiting | Phase 1 / Phase 2 | 20 | University of MiamiOTHER | 1 | Dec 8, 2025 | clinicaltrials |
| NCT06930846 | HOBSCOTCH-CA (HOme-Based Self-management and COgnitive Training CHanges Lives in Brain CAncer)(HOBSCOTCH-CA) | recruiting | N/A | 125 | Dartmouth-Hitchcock Medical CenterOTHER | 1 | Nov 21, 2025 | clinicaltrials |
Data updated 5 days agoSource updated Sep 24, 2026source: clinicaltrials